Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
PITTSBURGH, May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), an investigational, topical gene therapy for dystrophic epidermolysis bullosa (DEB)” at the Society for Investigative Dermatology 2022 Annual Meeting, taking place May 18-21 in Portland, Oregon.
GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), an investigational, topical gene therapy for dystrophic epidermolysis bullosa (DEB)
ePoster Presentation: Session 2, Genetic Disease, Gene Regulation, and Gene Therapy
The poster and ePoster will be available to conference attendees. To register for the conference, please visit SID 2022 Annual Meeting | Society for Investigative Dermatology. The Company will be present at Booth 218 to educate about DEB and the mechanism of the disease. Following the presentation, materials will be available to view online on the Investor section of th Company’s website.
About Dystrophic Epidermolysis Bullosa (DEB)
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have each granted B-VEC an orphan drug designation for the treatment of DEB. The FDA has also granted B-VEC fast track designation and rare pediatric designation for the treatment of DEB. In addition, in 2019, the FDA granted Regenerative Medicine Advanced Therapy (“RMAT”) to B-VEC for the treatment of DEB and the EMA granted PRIority MEdicines ("PRIME") eligibility for B-VEC to treat DEB.
About Krystal Biotech, Inc.
Source: Krystal Biotech, Inc.